Arcus Biosciences Inc RCUS:NYSE

Last Price$43.80NYSE Previous Close - Last Trade as of 7:00PM ET 11/30/21

Today's Change-1.32(2.93%)
Bid (Size)$40.00 (2)
Ask (Size)$48.06 (1)
Day Low / High$41.63 - 45.68
Volume1.1 M
 

View Biotechnology IndustryPeer Comparison as of 11/30/2021

 

Arcus Biosciences Inc ( NYSE )

Price: $43.80
Change: -1.32 (2.93%)
Volume: 1.1 M
7:00PM ET 11/30/2021
 
 

Insmed Inc ( NASDAQ )

Price: $27.52
Change: +0.40 (1.47%)
Volume: 1.0 M
4:00PM ET 11/30/2021
 
 

Cytokinetics Inc ( NASDAQ )

Price: $39.34
Change: +0.57 (1.47%)
Volume: 1.2 M
4:00PM ET 11/30/2021
 
 

ACADIA Pharmaceuticals Inc ( NASDAQ )

Price: $19.20
Change: +0.36 (1.91%)
Volume: 1.1 M
4:00PM ET 11/30/2021
 
 

Amicus Therapeutics Inc ( NASDAQ )

Price: $10.71
Change: -0.08 (0.74%)
Volume: 3.5 M
4:00PM ET 11/30/2021
 

Read more news Recent News

Berenberg Bank Adjusts Arcus Biosciences' Price Target to $68 From $60, Maintains Buy Rating
9:30AM ET 11/19/2021 MT Newswires

Arcus Biosciences (RCUS) has an average rating of buy and price targets ranging from $45 to $100, according to analysts polled by Capital IQ. (MT Newswires...

Citigroup Adjusts Price Target on Arcus Biosciences to $53 From $42, Reiterates Buy Rating
8:58AM ET 11/19/2021 MT Newswires

Arcus Biosciences (RCUS) has an average rating of buy and price targets ranging from $45 to $100, according to analysts polled by Capital IQ. (MT Newswires...

Barclays Adjusts Price Target on Arcus Biosciences to $60 From $48, Keeps Overweight Rating
8:35AM ET 11/19/2021 MT Newswires

Arcus Biosciences (RCUS) has an average investment rating of buy perform among analysts polled by Capital IQ, with a price target range of $45 to $100. (MT...

Wedbush Lifts Price Target on Arcus Biosciences to $67 From $52 After Gilead Opts In to 3 Programs; Outperform Rating Kept
7:45AM ET 11/19/2021 MT Newswires

Arcus Biosciences (RCUS) has an average rating of buy and price targets ranging from $45 to $100, according to analysts polled by Capital IQ. (MT Newswires...

Company Profile

Business DescriptionArcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA. View company web site for more details
Address3928 Point Eden Way
Hayward, California 94545
Phone+1.510.694.6200
Number of Employees108
Recent SEC Filing11/18/20218-K
Chairman & Chief Executive OfficerTerry J. Rosen
President & DirectorJuan Carlos Jaen
Chief Operating Officer & DirectorJennifer Jarrett
Chief Financial & Accounting OfficerRobert C. Goeltz

Company Highlights

Price Open$45.03
Previous Close$43.80
52 Week Range$22.36 - 49.10
Market Capitalization$3.1 B
Shares Outstanding70.2 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/23/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$4.10
Beta vs. S&P 500N/A
Revenue$8.4 M
Net Profit Margin-735.12%
Return on Equity-48.12%

Analyst Ratings as of 11/18/2021

Buy
10
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset